FASLG and neoplasm: Recently, another study found that blood concentration of FAS ligand (FASLG) was lower in 42 PanNEN G-3 compared to controls, and that positive FASLG immunoreactivity in tumor cells correlated with well-differentiated morphology (14/42 evaluable samples) [34]; suggesting that FASLG could be a future candidate biomarker.